Evaluation of the Efficacy and Safety of Curalin as Add-On Therapy in Adults With Type 2 Diabetes Mellitus
NCT ID: NCT05439473
Last Updated: 2022-06-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
51 participants
INTERVENTIONAL
2021-08-03
2022-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Curalin
Supplement capsules, 2 capsules, 3 times a day after meals. Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals.
Treatment
Curalin
Supplement capsules, 2 capsules, 3 times a day after meals. Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Curalin
Supplement capsules, 2 capsules, 3 times a day after meals. Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult patients (18-85 years of age) with Type II diabetes mellitus.
* HbA1c at screening is 8% - 11%.
* Body mass index (BMI)\>25.
* Stable body weight (±10%) within the 3 months preceding study entry.
* Patients were steadily treated with anti-diabetic medications, such as: GLP-1, Glucophage DPP-4 inhibitor or SGLT-2 inhibitor for at least 3 months or more prior to study entry.
* The patient must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period, and willing to return to the clinic for the follow up evaluation as specified in this protocol.
Exclusion Criteria
* Persons with known sensitivity to any of the components of the Curalin product.
* The patient has any clinically significant uncontrolled medical condition (treated or untreated).
* Patients with renal insufficiency (glomerular filtration rate \[GFR\]≤30 mL/min/1.73m2).
* Pregnant or lactating women. Women of child bearing potential will be administered a urine pregnancy test at study entry. All study participants will confirm their willingness to use birth control throughout the study.
* Patients deemed by the Investigator as unable to complete study participation.
* Patients currently treated with insulin or those that have been treated with insulin for more than 10 days in the 3 months prior to study entry.
* Use of medications known to modify glucose metabolism or to decrease the ability to recover from hypoglycemia such as oral, parenteral, local, dermal and inhaled steroids, and immunosuppressive or immunomodulating agents for more than a month prior to study entry, or during the study.
* Patient participated in a clinical study (investigational study drug or study device) within 30 days of the study entry.
* Life expectancy less than 1 year.
* History of stroke, transient ischemic attack, or myocardial infarction within six months prior to screening.
* Patients with uncontrolled hypertension defined as a systolic blood pressure ≥180 mmHg or a diastolic blood pressure ≥100mmHg.
* Patients who have thyroid stimulating hormone (TSH) levels \>1.5 times the upper limit of normal.
* Patients with significant liver disease or liver function impairment defined as any of the following; cirrhosis, hepatitis, biliary obstruction with hyperbilirubinemia (total bilirubin \>2 times the upper limit of normal) and aspartate aminotransferase (AST) or alanine aminotransferase levels (ALT) \>3 times the upper limit of normal.
* Patients with creatine kinase concentrations \> 10 times the upper limit of normal or creatine kinase elevation due to known muscle disease at visit 1 (screening 1).
* Laboratory abnormalities at screening including:
* Potassium \> 5.5 mEq/L
* Sodium ≤ 130 mEq/L
* Hemoglobin under 10 g/dl for Women or Under 11 g/dl for man.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CuraLife
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
DMC
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Cura-02
Identifier Type: -
Identifier Source: org_study_id